In order to increase Glimepiride bioavailability by bypassing first pass metabolism, buccal tablets were developed. The polymers HPMC K15M, Chitosan, Guar gum, and Carbopol-934 were chosen, and several formulations were created by combining these polymers in varied ratios. Chitosan Polymer is also employed in a 1:2 ratio to increase the formulation's solubility when the Glimepiride medication is poorly soluble in water. Angle of repose, bulk density, tapped density, Carr's index, and Hausner's ratio were all used to describe the pre-compression blend of Glimepiride buccal tablets. All results showed that the blend had good flow characteristics and superior compression qualities. The formulations made with Carbopal-934 and Chitosan at concentrations of 3 mg and 10 mg (F7) demonstrated superior 99.48% drug release and were subsequently improved. For the formulations that showed the desired drug release, swelling studies were conducted. Maximum flow and permeability coefficient values were displayed in the chosen formulations. Thus, the buccal tablets of Glimepride with increased bioavailability were effectively created, and they lower high blood sugar levels in persons with type 2 diabetes.